Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease (CURSOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02021110

Recruitment Status : Completed

First Posted : December 27, 2013

Last Update Posted : September 23, 2021

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Information provided by (Responsible Party):

Radboud University Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	October 2015
Actual Study Completion Date :	October 2015

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

D'Agnolo HM, Kievit W, Takkenberg RB, Riano I, Bujanda L, Neijenhuis MK, Brunenberg EJ, Beuers U, Banales JM, Drenth JP. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. J Hepatol. 2016 Sep;65(3):601-7. doi: 10.1016/j.jhep.2016.05.009. Epub 2016 May 17.

To Top